NCT02304458 2023-10-17Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasNational Cancer Institute (NCI)Phase 1/2 Completed140 enrolled 23 charts